First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.
Adv TherMay 23, 2026 (epub)
Zhenggang Ren, Tingbo Liang, Shanzhi Gu et al.
✦ AI-curated · Sources linked
In 30 seconds
This subgroup analysis of the randomized phase 3 KEYNOTE-966 study evaluated the efficacy of first-line pembrolizumab plus chemotherapy in 158 Chinese patients with advanced biliary tract cancer. The study found a median overall survival of 14.1 months in the pembrolizumab group compared to 9.9 months in the placebo group, indicating a significant survival benefit.
Key findings
- Median overall survival was 14.1 months in the pembrolizumab group versus 9.9 months in the placebo group.
- The objective response rate was 36.0% for pembrolizumab compared to 28.9% for placebo.
- Median duration of response was 10.2 months for pembrolizumab versus 5.7 months for placebo.
- Grade 3 or 4 treatment-related adverse events occurred in 71.6% of the pembrolizumab group.
Why it matters
The findings suggest that pembrolizumab combined with chemotherapy may improve overall survival in patients with advanced biliary tract cancer, providing a potential new treatment option in this challenging clinical setting.